{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:33:05Z","timestamp":1773466385869,"version":"3.50.1"},"reference-count":137,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen, the Norwegian Cancer Society","doi-asserted-by":"publisher","award":["100933"],"award-info":[{"award-number":["100933"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The protein kinase CK2 (also known as casein kinase 2) is one of the main contributors to the human phosphoproteome. It is regarded as a possible therapeutic strategy in several malignant diseases, including acute myeloid leukemia (AML), which is an aggressive bone marrow malignancy. CK2 is an important regulator of intracellular signaling in AML cells, especially PI3K\u2013Akt, Jak\u2013Stat, NF\u03baB, Wnt, and DNA repair signaling. High CK2 levels in AML cells at the first time of diagnosis are associated with decreased survival (i.e., increased risk of chemoresistant leukemia relapse) for patients receiving intensive and potentially curative antileukemic therapy. However, it is not known whether these high CK2 levels can be used as an independent prognostic biomarker because this has not been investigated in multivariate analyses. Several CK2 inhibitors have been developed, but CX-4945\/silmitasertib is best characterized. This drug has antiproliferative and proapoptotic effects in primary human AML cells. The preliminary results from studies of silmitasertib in the treatment of other malignancies suggest that gastrointestinal and bone marrow toxicities are relatively common. However, clinical AML studies are not available. Taken together, the available experimental and clinical evidence suggests that the possible use of CK2 inhibition in the treatment of AML should be further investigated.<\/jats:p>","DOI":"10.3390\/cancers15143711","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T01:12:28Z","timestamp":1690161148000},"page":"3711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"15","author":[{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[{"name":"Institute for Clinical Science, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway"},{"name":"Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-8411","authenticated-orcid":false,"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[{"name":"Institute for Clinical Science, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway"},{"name":"Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41392-021-00567-7","article-title":"Protein kinase CK2: A potential therapeutic target for diverse human diseases","volume":"6","author":"Borgo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021469","article-title":"Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death","volume":"369","author":"Litchfield","year":"2003","journal-title":"Biochem. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.385","article-title":"Protein kinase CK2 in hematologic malignancies: Reliance on a pivotal cell survival regulator by oncogenic signaling pathways","volume":"26","author":"Piazza","year":"2012","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1038\/onc.2016.86","article-title":"Targeting CK2-driven non-oncogene addiction in B-cell tumors","volume":"35","author":"Mandato","year":"2016","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Hatfield, K.J., Gr\u00f8nnings\u00e6ter, I.S., and Reikvam, H. (2020). The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082907"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Darici, S., Alkhaldi, H., Horne, G., J\u00f8rgensen, H.G., Marmiroli, S., and Huang, X. (2020). Targeting PI3K\/Akt\/mTOR in AML: Rationale and Clinical Evidence. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092934"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brenner, A.K., Andersson Tvedt, T.H., and Bruserud, \u00d8. (2016). The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells. Molecules, 21.","DOI":"10.3390\/molecules21111512"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Di Francesco, B., Verzella, D., Capece, D., Vecchiotti, D., Di Vito Nolfi, M., Flati, I., Cornice, J., Di Padova, M., Angelucci, A., and Alesse, E. (2022). NF-\u03baB: A Druggable Target in Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14143557"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.18632\/oncotarget.3545","article-title":"Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: From molecular pathogenesis to therapeutic target","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","article-title":"JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia","volume":"40","author":"Venugopal","year":"2020","journal-title":"Blood Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","article-title":"The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia","volume":"19","author":"Lee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/17474086.2015.971005","article-title":"STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia","volume":"8","author":"Bruserud","year":"2015","journal-title":"Expert. Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"32592","DOI":"10.1074\/jbc.M001358200","article-title":"Tumor necrosis factor alpha-induced phosphorylation of RelA\/p65 on Ser529 is controlled by casein kinase II","volume":"275","author":"Wang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2010-01-266320","article-title":"A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway","volume":"118","author":"Zheng","year":"2011","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation","volume":"276","author":"Torres","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20061837","article-title":"PTEN is destabilized by phosphorylation on Thr366","volume":"405","author":"Maccario","year":"2007","journal-title":"Biochem. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1097-2765(03)00358-7","article-title":"CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response","volume":"12","author":"Kato","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbrc.2008.07.082","article-title":"The human IKKbeta subunit kinase domain displays CK2-like phosphorylation specificity","volume":"374","author":"Shaul","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Song, J., and Bae, Y.S. (2021). CK2 Down-Regulation Increases the Expression of Senescence-Associated Secretory Phenotype Factors through NF-\u03baB Activation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010406"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.18632\/oncotarget.1852","article-title":"Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1\/3 and constitutive STAT3 activation","volume":"5","author":"Sommer","year":"2014","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102948","DOI":"10.1016\/j.dnarep.2020.102948","article-title":"Roles for MDC1 in cancer development and treatment","volume":"95","author":"Ruff","year":"2020","journal-title":"DNA Repair (Amst.)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BST20220754","article-title":"Mre11-Rad50: The DNA end game","volume":"51","author":"Hopfner","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1021\/acs.jmedchem.2c01523","article-title":"Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1756-8722-6-78","article-title":"Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity","volume":"6","author":"Gurrieri","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00412-014-0482-9","article-title":"DNA damage accumulation and repair defects in acute myeloid leukemia: Implications for pathogenesis, disease progression, and chemotherapy resistance","volume":"123","author":"Esposito","year":"2014","journal-title":"Chromosoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/1389450119666180110093713","article-title":"The Role of DNA Repair Pathways in AML Chemosensitivity","volume":"19","author":"Pearsall","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"L\u00e1inez-Gonz\u00e1lez, D., Alonso-Aguado, A.B., and Alonso-Dominguez, J.M. (2023). Understanding the Wnt Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Feasible Key against Relapses. Biology, 12.","DOI":"10.3390\/biology12050683"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"BSR20211841","DOI":"10.1042\/BSR20211841","article-title":"Targeting \u03b2-catenin in acute myeloid leukaemia: Past, present, and future perspectives","volume":"42","author":"Wagstaff","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00018-009-0108-1","article-title":"Dephosphorylation and inactivation of Akt\/PKB is counteracted by protein kinase CK2 in HEK 293T cells","volume":"66","author":"Brustolon","year":"2009","journal-title":"Cell Mol. Life Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2017.03.002","article-title":"Cross-talk between the CK2 and AKT signaling pathways in cancer","volume":"64","author":"Ruzzene","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymeth.2014.10.015","article-title":"Kinases, tails and more: Regulation of PTEN function by phosphorylation","volume":"77\u201378","author":"Fragoso","year":"2015","journal-title":"Methods"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5966\/sctm.2013-0166","article-title":"A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: A new tool to decipher their chemoresistance and self-renewal mechanisms","volume":"3","author":"Griessinger","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/stemcells.19-1-1","article-title":"New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of aml cells\u2014The present use in experimental studies and the possible importance for future therapeutic approaches","volume":"19","author":"Bruserud","year":"2001","journal-title":"Stem Cells"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2019.04.004","article-title":"Relationship between CD34\/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia","volume":"81","author":"Moshaver","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_37","first-page":"2657","article-title":"Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial","volume":"141","author":"Ngai","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1634\/stemcells.2007-0861","article-title":"Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia","volume":"26","author":"Moshaver","year":"2008","journal-title":"Stem Cells"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/17460441.2017.1356818","article-title":"Therapeutic targeting of leukemic stem cells in acute myeloid leukemia\u2014The biological background for possible strategies","volume":"12","author":"Bruserud","year":"2017","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41467-022-35624-4","article-title":"Early response evaluation by single cell signaling profiling in acute myeloid leukemia","volume":"14","author":"Tislevoll","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.18632\/oncotarget.3056","article-title":"Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells\u2014High expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation","volume":"6","author":"Bruserud","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.18632\/oncotarget.1195","article-title":"CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia","volume":"4","author":"Astori","year":"2013","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-06-1602","article-title":"Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia","volume":"13","author":"Kim","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Klink, M., Rahman, M.A., Song, C., Dhanyamraju, P.K., Ehudin, M., Ding, Y., Steffens, S., Bhadauria, P., Iyer, S., and Aliaga, C. (2021). Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13051127"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21291","DOI":"10.1074\/jbc.273.33.21291","article-title":"Protein kinase CK2alpha\u2019 is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation","volume":"273","author":"Orlandini","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/onc.2012.165","article-title":"Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction","volume":"32","author":"Deshiere","year":"2013","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.18632\/oncotarget.23422","article-title":"Under-expression of CK2\u03b2 subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival","volume":"9","author":"Vilardell","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.948","article-title":"Characterizing the convergence of protein kinase CK2 and caspase-3 reveals isoform-specific phosphorylation of caspase-3 by CK2\u03b1\u2019: Implications for pathological roles of CK2 in promoting cancer cell survival","volume":"4","author":"Turowec","year":"2013","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/A:1006808816770","article-title":"Multiple forms of protein kinase CK2 present in leukemic cells: In vitro study of its origin by proteolysis","volume":"191","author":"Roig","year":"1999","journal-title":"Mol. Cell Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Aaseb\u00f8, E., Berven, F.S., Bartaula-Brevik, S., Stokowy, T., Hovland, R., Vaudel, M., D\u00f8skeland, S.O., McCormack, E., Batth, T.S., and Olsen, J.V. (2020). Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. Cancers, 12.","DOI":"10.3390\/cancers12030709"},{"key":"ref_52","unstructured":"Bartaula-Brevik, S., Leitch, C., Hernandez-Valladares, M., Aaseb\u00f8, E., Berven, F.S., Selheim, F., Brenner, A.K., Rye, K.P., Hagen, M., and Reikvam, H. (2023). Pharmacological inhibition of vacuolar ATP-ase in primary acute myeloid leukemia cells: In vitro characterization of patient heterogeneity and in vivo studies of treatment toxicity. J. Clin. Med., submitted."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Firnau, M.B., and Brieger, A. (2022). CK2 and the Hallmarks of Cancer. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081987"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/leu.2016.209","article-title":"Protein kinase CK2 regulates AKT, NF-\u03baB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia","volume":"31","author":"Brancalion","year":"2017","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/10428194.2013.802781","article-title":"XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia","volume":"55","author":"Duicu","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13277-013-1110-7","article-title":"XRCC1 Arg399Gln variation and leukemia susceptibility: Evidence from 2647 cases and 5518 controls","volume":"35","author":"Huang","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e20200160","DOI":"10.1590\/1678-4685-gmb-2020-0160","article-title":"XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements","volume":"43","author":"Lopes","year":"2020","journal-title":"Genet. Mol. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","article-title":"Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies","volume":"98","author":"Gaymes","year":"2013","journal-title":"Haematologica"},{"key":"ref_61","first-page":"4625","article-title":"Inhibition of CK2\u03b1 and PI3K\/Akt synergistically induces apoptosis of CD34+CD38- leukaemia cells while sparing haematopoietic stem cells","volume":"30","author":"Cheong","year":"2010","journal-title":"Anticancer. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-06-0054","article-title":"Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_63","first-page":"4736","article-title":"The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells","volume":"62","author":"Dimri","year":"2002","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/leu.2015.331","article-title":"Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-019-0474-0","article-title":"Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity","volume":"33","author":"Ding","year":"2019","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-019-0270-0","article-title":"A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia","volume":"10","author":"Arriazu","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","article-title":"Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia","volume":"126","author":"Song","year":"2015","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Rosales, M., Rodr\u00edguez-Ulloa, A., Besada, V., Ram\u00f3n, A.C., P\u00e9rez, G.V., Ramos, Y., Guirola, O., Gonz\u00e1lez, L.J., Zettl, K., and Wi\u015bniewski, J.R. (2021). Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945. Cells, 10.","DOI":"10.1101\/2021.01.04.425248"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Salehi, B., Venditti, A., Sharifi-Rad, M., Kr\u0119giel, D., Sharifi-Rad, J., Durazzo, A., Lucarini, M., Santini, A., Souto, E.B., and Novellino, E. (2019). The Therapeutic Potential of Apigenin. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061305"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-021-01888-x","article-title":"Apigenin role as cell-signaling pathways modulator: Implications in cancer prevention and treatment","volume":"21","author":"Javed","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.mehy.2020.109723","article-title":"Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy","volume":"141","author":"McCarty","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1086894","DOI":"10.3389\/fphar.2022.1086894","article-title":"Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26\/DPP4 on colorectal carcinoma cells","volume":"13","author":"Fux","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/EP086826","article-title":"Casein kinase 2 inhibition impairs spontaneous and oxytocin-induced contractions in late pregnant mouse uterus","volume":"103","author":"Suhas","year":"2018","journal-title":"Exp. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0163-7258(02)00185-7","article-title":"Toward the rational design of protein kinase casein kinase-2 inhibitors","volume":"93","author":"Sarno","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Brenner, A.K., and Bruserud, \u00d8. (2019). Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype. Cancers, 11.","DOI":"10.3390\/cancers11070973"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bruserud, \u00d8., Reikvam, H., and Brenner, A.K. (2022). Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. Molecules, 27.","DOI":"10.3390\/molecules27030735"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-019-0050-0","article-title":"Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells","volume":"4","author":"Nepstad","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gruszka, A.M., Valli, D., and Alcalay, M. (2019). Wnt Signalling in Acute Myeloid Leukaemia. Cells, 8.","DOI":"10.3390\/cells8111403"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3324\/haematol.10148","article-title":"Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells","volume":"92","author":"Bruserud","year":"2007","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.scr.2015.09.008","article-title":"The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells","volume":"15","author":"Reikvam","year":"2015","journal-title":"Stem Cell Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00432-017-2458-7","article-title":"The constitutive protease release by primary human acute myeloid leukemia cells","volume":"143","author":"Honnemyr","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/14728222.2017.1300255","article-title":"Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism","volume":"21","author":"Brenner","year":"2017","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: Coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.22180","article-title":"Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts","volume":"119","author":"Hatfield","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2008.07411.x","article-title":"Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators","volume":"144","author":"Hatfield","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1684\/ecn.2012.0322","article-title":"The angioregulatory cytokine network in human acute myeloid leukemia\u2014From leukemogenesis via remission induction to stem cell transplantation","volume":"23","author":"Reikvam","year":"2012","journal-title":"Eur. Cytokine Netw."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1100\/tsw.2011.92","article-title":"Toll-like receptors in angiogenesis","volume":"11","author":"Grote","year":"2011","journal-title":"Sci. World J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00441-019-03119-2","article-title":"Toll-like receptor bioactivity in endothelial progenitor cells","volume":"379","author":"Heidarzadeh","year":"2020","journal-title":"Cell Tissue Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1096\/fj.201701536R","article-title":"Endothelial microRNAs regulating the NF-\u03baB pathway and cell adhesion molecules during inflammation","volume":"32","author":"Zhong","year":"2018","journal-title":"FASEB J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2019.00085","article-title":"Cell Type-Specific Roles of NF-\u03baB Linking Inflammation and Thrombosis","volume":"10","author":"Mussbacher","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Aaseb\u00f8, E., Brenner, A.K., Hernandez-Valladares, M., Birkeland, E., Mjaavatten, O., Reikvam, H., Selheim, F., Berven, F.S., and Bruserud, \u00d8. (2021). Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. Diseases, 9.","DOI":"10.3390\/diseases9040074"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fimmu.2017.00106","article-title":"Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms","volume":"8","author":"Brenner","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_94","first-page":"391","article-title":"Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts","volume":"89","author":"Bruserud","year":"2004","journal-title":"Haematologica"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Jimi, E., Takakura, N., Hiura, F., Nakamura, I., and Hirata-Tsuchiya, S. (2019). The Role of NF-\u03baB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-\u03baB Inhibition \u201cKilling Two Birds with One Stone\u201d?. Cells, 8.","DOI":"10.3390\/cells8121636"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Hong, H., and Benveniste, E.N. (2021). The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121932"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20110132","article-title":"The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in","volume":"208","author":"Ehninger","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rundgren, I.M., Ryningen, A., Anderson Tvedt, T.H., Bruserud, \u00d8., and Ersv\u00e6r, E. (2020). Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes. Molecules, 25.","DOI":"10.3390\/molecules25020367"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.intimp.2010.06.004","article-title":"Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-kappaB and AP-1 activation","volume":"10","author":"Jung","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e2107044118","DOI":"10.1073\/pnas.2107044118","article-title":"Regulation of TLR4 signaling through the TRAF6\/sNASP axis by reversible phosphorylation mediated by CK2 and PP4","volume":"118","author":"Yang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000258867.79411.96","article-title":"Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis","volume":"27","author":"Harvey","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/bs.apcsb.2020.09.003","article-title":"Protein kinase CK2 inhibition as a pharmacological strategy","volume":"124","author":"Borgo","year":"2021","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Piccini, M., Mannelli, F., and Coltro, G. (2023). The Role of Venetoclax in Relapsed\/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Bioengineering, 10.","DOI":"10.3390\/bioengineering10050591"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"El-Cheikh, J., Bidaoui, G., Saleh, M., Moukalled, N., Abou Dalle, I., and Bazarbachi, A. (Clin. Hematol. Int., 2023). Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome, Clin. Hematol. Int., ahead of print.","DOI":"10.1007\/s44228-023-00041-x"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.20517\/cdr.2022.108","article-title":"Targeting regulated cell death pathways in acute myeloid leukemia","volume":"6","author":"Garciaz","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41375-022-01627-9","article-title":"Tipping the balance: Toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma","volume":"36","author":"Thus","year":"2022","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"935023","DOI":"10.3389\/fcell.2022.935023","article-title":"Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma","volume":"10","author":"Manni","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3324\/haematol.2022.281668","article-title":"Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation","volume":"108","author":"Thus","year":"2023","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: Lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Aaseb\u00f8, E., Brenner, A.K., Birkeland, E., Tvedt, T.H.A., Selheim, F., Berven, F.S., and Bruserud, \u00d8. (2021). The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells-A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells. Cancers, 13.","DOI":"10.3390\/cancers13071509"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: A small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1200\/jco.2011.29.15_suppl.3087","article-title":"Findings from the phase 1 clinical trial of CX-4945, an orally available inhibitor of CK2","volume":"29","author":"Marschke","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tranon.2018.09.005","article-title":"Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma","volume":"12","author":"Zakharia","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep.32804","article-title":"Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced\/metastatic cholangiocarcinoma: A Phase 1b\/2 study","volume":"77","author":"Borad","year":"2023","journal-title":"Hepatology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"590266","DOI":"10.3389\/fimmu.2020.590266","article-title":"Myeloid Cell CK2 Regulates Inflammation and Resistance to Bacterial Infection","volume":"11","author":"Larson","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/acs.jmedchem.2c01887","article-title":"Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3\u03b2 and DYRK1A Kinases: A Structural Perspective","volume":"66","author":"Grygier","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e154839","DOI":"10.1172\/JCI154839","article-title":"Relieving DYRK1A repression of MKL1 confers an adult-like phenotype to human infantile megakaryocytes","volume":"132","author":"Elagib","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20150002","article-title":"DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3","volume":"212","author":"Thompson","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygeno.2004.08.021","article-title":"DYRK gene structure and erythroid-restricted features of DYRK3 gene expression","volume":"85","author":"Zhang","year":"2005","journal-title":"Genomics"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2174\/092986708784638834","article-title":"The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemia","volume":"15","author":"Holmes","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.stemcr.2015.12.010","article-title":"GSK3\u03b2 Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells","volume":"6","author":"Maufort","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1089\/scd.2014.0230","article-title":"Small-molecule inhibitor of glycogen synthase kinase 3\u03b2 6-Bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice","volume":"24","author":"Shen","year":"2015","journal-title":"Stem Cells Dev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1634\/stemcells.2007-0600","article-title":"Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth","volume":"26","author":"Holmes","year":"2008","journal-title":"Stem Cells"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jim-2016-000076","article-title":"Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia","volume":"64","author":"Francis","year":"2016","journal-title":"J. Investig. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.it.2020.06.004","article-title":"Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice","volume":"41","author":"Saito","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","article-title":"Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting","volume":"49","author":"Wu","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Reyes-Garau, D., Ribeiro, M.L., and Rou\u00e9, G. (2019). Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications. Cancers, 11.","DOI":"10.3390\/cancers11101483"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/17474086.2015.1036025","article-title":"Emerging therapeutic targets in human acute myeloid leukemia (part 2)\u2014Bromodomain inhibition should be considered as a possible strategy for various patient subsets","volume":"8","author":"Reikvam","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2040620718816698","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic therapy combinations in acute myeloid leukemia: What are the options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: Mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymgme.2020.05.005","article-title":"Metabolomics in acute myeloid leukemia","volume":"130","author":"Wojcicki","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Roffey, S.E., and Litchfield, D.W. (2021). CK2 Regulation: Perspectives in 2021. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101361"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clml.2021.03.009","article-title":"Leukemic Stem Cell CD34+CD38\u2212TIM3+Frequency in Patients with Acute Myeloid Leukemia: Clinical Implications","volume":"21","author":"Mohamed","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: A prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","article-title":"A clinically relevant population of leukemic CD34(+)CD38(\u2212) cells in acute myeloid leukemia","volume":"119","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-22-2237","article-title":"Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia","volume":"29","author":"Canali","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:16:38Z","timestamp":1760127398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":137,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15143711"],"URL":"https:\/\/doi.org\/10.3390\/cancers15143711","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}